Results 31 to 40 of about 24,954,598 (334)

Focus on chirality of HIV-​1 non-​nucleoside reverse transcriptase inhibitors [PDF]

, 2016
Chiral HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) are of great interest since one enantiomer is often more potent than the corresponding counterpart against the HIV-1 wild type (WT) and the HIV-1 drug resistant mutant strains.
Famiglini, Valeria, Silvestri, Romano
core   +2 more sources

Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies

Nature reviews. Immunology, 2022
After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive. There are many reasons why the development of a potent and durable HIV-1 vaccine is challenging, including the extraordinary genetic diversity of HIV-1 and its ...
B. Haynes, K. Wiehe, P. Borrow, K. Saunders, Bette Korber, K. Wagh, A. McMichael, G. Kelsoe, B. Hahn, F. Alt, G. Shaw   +10 more
semanticscholar   +1 more source

Host mRNA decay proteins influence HIV-1 replication and viral gene expression in primary monocyte-derived macrophages

Retrovirology, 2019
Background Mammalian cells harbour RNA quality control and degradative machineries such as nonsense-mediated mRNA decay that target cellular mRNAs for clearance from the cell to avoid aberrant gene expression.
Shringar Rao, Raquel Amorim, Meijuan Niu, Yann Breton, Michel J. Tremblay, Andrew J. Mouland   +5 more
doaj   +1 more source

Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study

PLoS ONE, 2015
Introduction The use of anti-retroviral therapy (ART) has dramatically reduced HIV-1 associated morbidity and mortality. However, HIV-1 infected individuals have increased rates of morbidity and mortality compared to the non-HIV-1 infected population and
Daniel D. Murray, Kazuo Suzuki, M. Law, J. Trebicka, J. Neuhaus, D. Wentworth, M. Johnson, M. Vjecha, A. Kelleher, S. Emery   +9 more
semanticscholar   +1 more source

Effector memory differentiation increases detection of replication-competent HIV-l in resting CD4+ T cells from virally suppressed individuals. [PDF]

, 2019
Studies have demonstrated that intensive ART alone is not capable of eradicating HIV-1, as the virus rebounds within a few weeks upon treatment interruption.
Bale, Michael J, Busch, Michael P, Cox, Bryan, Deeks, Steven G, Hoh, Rebecca, Kearney, Mary F, Kulpa, Deanna A, Lackman-Smith, Carol, Maldarelli, Frank, Ptak, Roger G, Stone, Mars, Subramanian, Krupa, Wiegand, Ann, Wonderlich, Elizabeth R   +13 more
core   +1 more source

Rectal Microbiome Composition Correlates with Humoral Immunity to HIV-1 in Vaccinated Rhesus Macaques. [PDF]

, 2019
The microbiome is an integral and dynamic component of the host and is emerging as a critical determinant of immune responses; however, its influence on vaccine immunogenicity is largely not well understood.
Dinasarapu, Ashok R, Durbin-Johnson, Blythe P, Elizaldi, Sonny R, Iyer, Smita S, Kozlowski, Pamela A, Raeman, Reben, Rolston, Matthew, Settles, Matthew, Verma, Anil, Walter, Korey A   +9 more
core   +1 more source

HIV-1 induces in vivo platelet activation by enhancing platelet NOX2 activity. [PDF]

, 2015
OBJECTIVES: HIV-1 patients show increased platelet activation, but the mechanisms involved are not completely clarified. We speculated that HIV-1 might induce in vivo platelet activation by enhancing platelet NOX2-related oxidative stress.
Bartimoccia, Simona, Carnevale, Roberto, Di Campli, Francesco, Esposito, Antonella, Fantauzzi, Alessandra, Mezzaroma, Ivano, Novo, Marta, Pastori, Daniele, Pignatelli, Pasquale, Violi, Francesco   +9 more
core   +1 more source

Lenacapavir: a first-in-class HIV-1 capsid inhibitor.

Current Opinion in HIV and AIDS, 2022
PURPOSE OF REVIEW This review summarizes available data for lenacapavir, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral life cycle.
H. Dvory‐Sobol, Naveed A Shaik, C. Callebaut, M. Rhee   +3 more
semanticscholar   +1 more source

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.

New England Journal of Medicine, 2015
BACKGROUND Antiretroviral preexposure prophylaxis has been shown to reduce the risk of human immunodeficiency virus type 1 (HIV-1) infection in some studies, but conflicting results have been reported among studies, probably due to challenges of ...
J. Molina, C. Capitant, B. Spire, G. Pialoux, L. Cotte, I. Charreau, C. Tremblay, J. Le Gall, E. Cua, A. Pasquet, F. Raffi, C. Pintado, C. Chidiac, J. Chas, P. Charbonneau, C. Delaugerre, M. Suzan-Monti, B. Loze, J. Fonsart, G. Peytavin, A. Chéret, J. Timsit, G. Girard, N. Lorente, M. Préau, J. Rooney, M. Wainberg, D. Thompson, W. Rozenbaum, V. Doré, L. Marchand, M. Simon, N. Etien, J. Aboulker, L. Meyer, J. Delfraissy   +35 more
semanticscholar   +1 more source

Interaction vesicles as emerging mediators of host‐pathogen molecular crosstalk and their implications for infection dynamics

FEBS Letters, EarlyView.
Interaction extracellular vesicles (iEVs) are hybrid vesicles formed through host‐pathogen communication. They facilitate immune evasion, transfer pathogens' molecules, increase host cell uptake, and enhance virulence. This Perspective article illustrates the multifunctional roles of iEVs and highlights their emerging relevance in infection dynamics ...
Bruna Sabatke, Izadora Volpato Rossi, Marcel I. Ramirez   +2 more
wiley   +1 more source